184576-27-0

Upstream product

• 55696-50-9 tert-butyl 4-cyanobenzoate 
• 6068-72-0 4-cyanobenzoyl chlorIde 
• 619-65-8 4-cyanobenzoic Acid 

Downstream Products

• 340736-80-3 ethyl 3-[4-(tert-butoxycarbonyl)phenyl]-1,2,4-oxadiazole-5-carboxylate 
• 340736-79-0 tert-butyl 4-(1,2,4-oxadiazol-3-yl)benzoate 
• 340736-83-6 4-(1,2,4-oxadiazol-3-yl)benzoic acid 
• 340736-86-9 4-(5-methoxy-1,2,4-oxadiazol-3-yl)benzoic acid 
• 340736-78-9 4-(2-oxo-2,3-dihydro-1,2λ⁴,3,5-oxathiadiazol-4-yl)benzoic acid 
• 340736-84-7 4-(5-cyano-1,2,4-oxadiazol-3-yl)benzoic acid 
• 340736-85-8 tert-butyl 4-(5-methoxy-1,2,4-oxadiazol-3-yl)benzoate 
• 340736-82-5 tert-butyl 4-(5-cyano-1,2,4-oxadiazol-3-yl)benzoate 
• 340736-81-4 tert-butyl 4-(5-carbamoyl-1,2,4-oxadiazol-3-yl)benzoate 
• 340736-49-4 methyl 2-[(2S)-4-[2-(tert-butoxy)-2-oxoethyl]-1-[(2S)-3-(4-methoxyphenyl)-2-[[4-(1,2,4-oxadiazol-3-yl)benzoyl]amino]propanoyl]-3-oxopiperazinyl]acetate 
• 340736-45-0 methyl 2-[(2S)-4-[2-(tert-butoxy)-2-oxoethyl]-1-[(2S)-3-(4-methoxyphenyl)-2-[[4-(2-oxo-2,3-dihydro-1,2,λ⁴,3,5-oxathiadiazol-3-yl)benzoyl]amino]propanoyl]-3-oxopiperazinyl]acetate 
• 340736-51-8 methyl 2-[(2S)-4-[2-(tert-butoxy)-2-oxoethyl]-1-[[(2S)-2-[4-(5-methoxy-1,2,4-oxadiazol-3-yl)benzoyl]amino]-3-(methoxyphenyl)propanoyl]-3-oxopiperazinyl]acetate 
• 340736-50-7 methyl 2-[(2S)-4-[2-(tert-butoxy)-2-oxoethyl]-1-[(2S)-2-[[4-(5-cyano-1,2,4-oxadiazol-3-yl)benzoyl]amino]-3-(4-methoxyphenyl)propanoyl]-3-oxopiperazinyl]cetate 
• 1259946-96-7 4-[(2-thiophenecarbonyl)oxyamidino]benzoic acid tert-butyl ester 

Relevant academic research and scientific papers

Structural optimization of azadipeptide nitriles strongly increases association rates and allows the development of selective cathepsin inhibitors

Using the example of cathepsin K, we demonstrate the design of highly potent and selective azadipeptide nitrile inhibitors. A systematic scan with respect to P2 and P3 substituents was carried out. Structural modifications strongly affected the enzyme-inh

Orally active GPIIb/IIIa antagonists: Synthesis and biological activities of masked amidines as prodrugs of 2-[(3S)-4-[(2S)-2-(4-amidinobenzoylamino)-3-(4-methoxyphenyl)propanoyl]-3- (2-methoxy-2-oxoethyl)-2-oxopiperazinyl]acetic acid

To improve the in vivo potency of the potent GPIIb/IIIa antagonist 2-[(3S)-4-[(2S)-2-(4-amidinobenzoylamino)-3-(4-methoxyphenyl)propanoyl]-3- (2-methoxy-2-oxoethyl)-2-oxopiperazinyl]lacetic acid (4), the amidino group was converted to an oxadiazole ring, thiadiazole ring of substituted amidoxime group. These groups were expected to be metabolized to an amidino group in vivo. The compounds synthesized were evaluated for their potency to inhibit the ex vivo adenosine 5′-diphosphate (ADP)-induced aggregation of guinea pig platelets. Among the compounds examined, the methoxycarbonyloxyamidine 8a exhibited the most potent ex vivo inhibitory activity with a fast onset and prolonged duration of action after oral administration.